The advent of implantable bioelectronic devices offers prospective solutions toward health monitoring and disease diagnosis and treatments. However, advances in power modules have lagged far behind the tissue-integrated sensor nodes and circuit units. Here, we report a soft implantable power system that monolithically integrates wireless energy transmission and storage modules. The energy storage unit comprises biodegradable Zn-ion hybrid supercapacitors that use molybdenum sulfide (MoS ₂ ) nanosheets as cathode, ion-crosslinked alginate gel as electrolyte, and zinc foil as anode, achieving high capacitance (93.5 mF cm ⁻² ) and output voltage (1.3 V). Systematic investigations have been conducted to elucidate the charge storage mechanism of the supercapacitor and to assess the biodegradability and biocompatibility of the materials. Furthermore, the wirelessly transmitted energy can not only supply power directly to applications but also charge supercapacitors to ensure a constant, reliable power output. Its power supply capabilities have also been successfully demonstrated for controlled drug delivery.

To evaluate the relationship between periodontitis and postmenopausal osteoporosis. This research was carried out according to the principles laid down by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guideline statement. We searched the Web of Science, Embase, PubMed, The Cochrane Library, CNKI, VIP, and WanFang databases from inception to July 1, 2023 to collect all relevant publications, with no restrictions on publication date or Languages. Cochrane's tool for assessing RoB was used to evaluate the RoB for RCTs. The Newcastle-Ottawa Scale was used to assess the RoB for cohort studies and case-control studies. Mean differences (MD) with 95 % confidence intervals (CI) were used for analysis of continuous data. Heterogeneity was measured using the I² statistic. Revman 5.4 software was used for the meta-analysis. 28 observational studies with 19611 patients, including 5813 cases in the postmenopausal osteoporosis group and 13798 cases in the non-osteoporosis group. The studies showed that the degrees of clinical attachment loss (CAL), probing depth (PD), gingival recession (GR), simplified oral hygiene index (OHIS), and percentage of sites with bleeding on probing (BOP) in the postmenopausal osteoporosis group were higher than those in the non-osteoporosis group[CAL(MD = 0.89(mm), 95 % CI [0.48,1.30], p < 0.00001), PD (MD = 0.27(mm), 95 % CI [0.13, 0.41], p = 0.0001), GR (MD = 0.28(mm), 95 % CI [0.20, 0.35], p < 0.00001), OHIS (MD = 1.32,95 % CI [1.12,1.51], p < 0.00001), BOP(MD = 12.71(%), 95 % CI [3.24,22.18], p = 0.009)]. Eleven studies found that bone mineral density (BMD) in the postmenopausal osteoporosis group was lower than that in non-osteoporosis group (MD = −0.41(U/cm²), 95 % CI [-0.77,-0.05], p = 0.03). The combined analysis results of the studies in the two groups showed that there were no significant differences in the loss of alveolar crestal height (ACH)[(MD = −1.76(%),95%CI [-3.64,0.12], p = 0.07)]. Postmenopausal osteoporosis patients are more likely to suffer from periodontitis, and the condition is easily aggravated.

Evodiamine inactivates NF-κB and potentiates the antitumor effects of gemcitabine on tongue cancer both in vitro and in vivo Qi Guo,1 Yanmei Liu,1 Jiayuan Zhao,1 Jing Wang,1 Yue Li,1 Yunqing Pang,1 Jian Chen,2 Jing Wang1 1Department of Periodontology, School of Stomatology, Lanzhou University, Lanzhou, Gansu, China; 2Department of Pediatric Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, China Objective: The aim of this study was to investigate whether evodiamine (EVO) could potentiate the antitumor activity of gemcitabine (GEM) in tongue cancer cells and determine its potential underlying mechanisms. Materials and methods: Human Tca8113 and CAL-27 tongue squamous carcinoma cell lines were treated with EVO and GEM in different sequences and doses, after which cell proliferation was measured. Drug interactions were analyzed using the Chou–Talalay method with CompuSyn software. Clonality, apoptosis, and migration were measured using the plate clone formation assay, annexin V/propidium iodide (PI) staining, Hoechst 33342 staining, and the wound-healing test. The activity of the nuclear factor kappa light-chain enhancer of activated B cell (NF-κB) p65 subunit and its downstream proteins was quantified by Western blotting. The effects of the drug combination in vivo were assessed using a CAL-27 heterotopic xenograft model. Results: EVO and GEM had synergistic effects on CAL-27 and Tca8113 cell lines in time- and concentration-dependent manners. Combination of drugs inhibited cell proliferation and migration and reduced the expression of NF-κB p65, B cell lymphoma 2 (Bcl-2), and B cell lymphoma extra large (Bcl-xl) compared with the control and either drug alone. In vivo, combination treatment of the xenograft model with EVO and GEM led to a significant reduction in tumor volume growth and inhibited the activation of NF-κB p65 with no obvious adverse reactions. Conclusion: The results of this study showed that EVO may inhibit cancer cells by suppressing NF-κB activity, and in combination with GEM, it may increase the chemosensitivity of tongue squamous cancer cells, thereby improving the treatment response. Keywords: tongue cancer, evodiamine, gemcitabine, combination index, apoptosis, NF-κB